Live feed
Filing
SCHEDULE 13G/A
SCHEDULE 13G/A0000919574-25-005042·Compass Therapeutics, Inc.
Schedule 13G ownership disclosure
Compass Therapeutics Inc
Common Stock, $0.0001 par value per share · CUSIP: 20454B104
Event date: 2025-08-13
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Suvretta Capital Management, LLC
Shares: 14,101,159.00 · Class: 8.2%
- Averill Master Fund, Ltd.
Shares: 12,229,050.00 · Class: 7.1%
- Aaron Cowen
Shares: 14,101,159.00 · Class: 8.2%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000919574-25-005042
- Form type
- SCHEDULE 13G/A
- Filer
- Compass Therapeutics, Inc.
- CIK
- CIK 1738021
- Filed
- Aug 21, 2025
- Reporting period
- Aug 13, 2025
- Description
- Schedule 13G beneficial ownership